1.41

0.71% 0.01

Therapeuticsmd Inc (TXMD)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.40

Offen:

$1.41

24-Stunden-Volumen:

6,614

Relative Volume:

0.43

Marktkapitalisierung:

$16.16M

Einnahmen:

$996.00K

Nettoeinkommen (Verlust:

$-6.09M

KGV:

0.314

EPS:

4.49

Netto-Cashflow:

$-9.76M

1W Leistung:

+5.22%

1M Leistung:

-11.32%

6M Leistung:

-34.11%

1J Leistung:

-49.46%

1-Tages-Spanne:

$1.40

$1.4165

1-Wochen-Bereich:

$1.32

$1.44

52-Wochen-Spanne:

$1.15

$2.9899

Therapeuticsmd Inc Stock (TXMD) Company Profile

Firmenname

Therapeuticsmd Inc

Sektor

Healthcare (1200)

Branche

Drug Manufacturers - Specialty & Generic (87)

Telefon

561-961-1900

Adresse

951 YAMATO ROAD, SUITE 220, BOCA RATON, FL

Mitarbeiter

Twitter

@TherapeuticsMD

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

TXMD's Discussions on Twitter

Vergleichen Sie TXMD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TXMD Therapeuticsmd Inc	1.41	16.16M	996.00K	-6.09M	-9.76M	4.49
ZTS Zoetis Inc	176.74	80.59B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.72	44.17B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.57	42.61B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.57	18.77B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.22	15.73B	15.05B	-883.30M	1.89B	1.53

Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2020-08-07	Herabstufung	Jefferies	Hold → Underperform
2020-05-19	Herabstufung	JP Morgan	Overweight → Neutral
2019-12-02	Eingeleitet	Guggenheim	Buy
2019-10-17	Eingeleitet	H.C. Wainwright	Buy
2019-04-30	Fortgesetzt	Noble Capital Markets	Outperform
2018-06-15	Eingeleitet	JP Morgan	Overweight
2017-09-08	Eingeleitet	Morgan Stanley	Equal-Weight
2017-07-11	Hochstufung	Oppenheimer	Perform → Outperform
2017-05-09	Herabstufung	Oppenheimer	Outperform → Perform
2016-11-22	Fortgesetzt	Jefferies	Buy
2016-11-22	Eingeleitet	Oppenheimer	Outperform
2016-11-07	Fortgesetzt	Guggenheim	Buy
2016-04-04	Eingeleitet	Goldman	Buy
2015-12-08	Bestätigt	Jefferies	Buy
2015-12-08	Bestätigt	Stifel	Buy
2015-09-21	Bestätigt	Jefferies	Buy
2015-06-09	Eingeleitet	Guggenheim	Buy
2014-07-08	Eingeleitet	FBR Capital	Outperform
2014-04-17	Bestätigt	Noble Financial	Buy
2014-01-28	Bestätigt	Noble Financial	Buy

Alle ansehen

Therapeuticsmd Inc Aktie (TXMD) Neueste Nachrichten

Nov 26, 2024

TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Nov 26, 2024

Nov 25, 2024

TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch

Nov 25, 2024

Nov 22, 2024

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Nov 22, 2024

Nov 21, 2024

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Nov 21, 2024

Nov 20, 2024

TXMD (TherapeuticsMD) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 19, 2024

TherapeuticsMD Inc. stock rises Tuesday, still underperforms market - MarketWatch

Nov 19, 2024

Nov 18, 2024

TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch

Nov 18, 2024

Nov 15, 2024

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch

Nov 15, 2024

TXMD stock touches 52-week low at $1.43 amid market challenges - Investing.com

Nov 15, 2024

TherapeuticsMD Third Quarter 2024 Earnings: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

TherapeuticsMD, Inc. (NASDAQ:TXMD) Sees Large Increase in Short Interest - Defense World

Nov 15, 2024

Nov 13, 2024

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch

Nov 13, 2024

Nov 12, 2024

TherapeuticsMD Reports Reduced Losses Amid Strategic Shift - TipRanks

Nov 12, 2024

TherapeuticsMD: Q3 Earnings Snapshot - Houston Chronicle

Nov 12, 2024